NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Status:
Completed
Trial end date:
2015-02-18
Target enrollment:
Participant gender:
Summary
This randomized, parallel cohort, two stage, double-blind, placebo-controlled study evaluated
the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in
HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer prior to surgery
(neo-adjuvant setting).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborators:
Breast International Group German Breast Group German Breast Group (GBG) SOLTI Breast Cancer Research Group